After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
St. Vincent will expand its footprint in central Indiana by opening eight small hospitals where patients can get treated for medical conditions that aren’t life-threatening. The first four locations were announced Monday.
Over the last eight years, Eli Lilly relied on a three-decade company veteran to steer it through declining sales and a struggling product pipeline. Now, it’ll rely on another long-time executive for its next chapter.
A hot-selling drug for diabetes sold by Eli Lilly and Co. and a co-partner just got another potential boost, as a government panel narrowly recommended that the companies should be allowed to claim that the drug cuts the risk of cardiovascular death.